Biogen (BIIB) Osake Kurssi
Biogen Kurssi
Liikevaihto on kasvanut 7,1 % vuodessa viimeisten 19 vuoden aikana 9,89 Mrd. USD:een. Osakekohtainen tulos on kasvanut 14,9 % vuodessa viimeisten 19 vuoden aikana. Biogenn nettomarginaali on nyt 13,1 %, laskenut 14,2 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 240,00 USD, eli yli nykyhintaa 9,2 %. 43 analyytikosta 30 suosittaa ostoa — kokonaiskonsensus on Osta.
Biogen osakekurssi
Biogen liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Biogen -osakkeesta
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analyytikot asettavat tällä hetkellä Biogen-osakkeelle keskimääräisen tavoitehinnan 238,69 USD (mediaani: 240,00 USD), mikä merkitsee +8,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 43 analyytikkoarvioon.
43 analyytikkoa arvioi tällä hetkellä Biogen-osaketta: 30 suosittaa ostoa, 12 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Biogen-yhtiöltä 10,45 Mrd. USD liikevaihtoa ja 12,42 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Biogen-osake noteerataan hintaan 195,45 EUR (219,88 USD).
Biogen-osake (BIIB) on listattuna 11 pörssissä, muun muassa: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
odotettu liikevaihto Biogen on 10,45 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Biogen on 1,83 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Biogen:n hinta-voitto-suhde (P/E) on tällä hetkellä 17,71. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Biogen-osakkeen arvostusta.
Biogen:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,09. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Biogen-osakkeen arvostuskennuslukuna.
Biogen:n Eulpool-laatuscore on 3/10.
Biogen:n ISIN on US09062X1037. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Biogen:n WKN on 789617. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Biogen:n ticker on BIIB. Tämä pörssinoteeraus käytetään Biogen-osakkeiden kauppaan pörssissä.
Biogen osake
Biogen vertaisryhmä
Biogen Ticker
Biogen FIGI
Kaikki tunnusluvut ja syvällinen analyysi Biogen:sta
Meidän osakeanalyysimme Biogen-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Biogen:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: